IRIS
TOGNOLINI, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.035
AS - Asia 6.498
EU - Europa 6.267
SA - Sud America 907
AF - Africa 394
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 2
Totale 24.113
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.799
SG - Singapore 2.155
IT - Italia 1.855
CN - Cina 1.850
VN - Vietnam 1.094
FI - Finlandia 840
IE - Irlanda 753
SE - Svezia 730
BR - Brasile 720
DE - Germania 662
HK - Hong Kong 442
UA - Ucraina 329
FR - Francia 252
ZA - Sudafrica 250
BD - Bangladesh 219
GB - Regno Unito 200
NL - Olanda 186
TR - Turchia 184
IN - India 164
CA - Canada 134
RU - Federazione Russa 115
AR - Argentina 78
BE - Belgio 65
AT - Austria 64
CI - Costa d'Avorio 56
MX - Messico 56
JP - Giappone 49
ID - Indonesia 46
IQ - Iraq 45
KR - Corea 37
RO - Romania 36
CZ - Repubblica Ceca 35
EC - Ecuador 34
PH - Filippine 34
ES - Italia 31
TH - Thailandia 29
PK - Pakistan 27
PL - Polonia 25
JO - Giordania 19
VE - Venezuela 19
LT - Lituania 18
CM - Camerun 17
CO - Colombia 17
MA - Marocco 15
SA - Arabia Saudita 14
TN - Tunisia 13
CL - Cile 12
EG - Egitto 12
CH - Svizzera 11
UZ - Uzbekistan 11
MY - Malesia 10
EU - Europa 9
JM - Giamaica 9
PA - Panama 9
AL - Albania 8
BO - Bolivia 8
KE - Kenya 8
NP - Nepal 8
PY - Paraguay 8
AZ - Azerbaigian 7
CR - Costa Rica 7
HU - Ungheria 7
KG - Kirghizistan 7
TW - Taiwan 7
BG - Bulgaria 6
HN - Honduras 6
PE - Perù 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
KZ - Kazakistan 5
LB - Libano 5
SI - Slovenia 5
SN - Senegal 5
DO - Repubblica Dominicana 4
EE - Estonia 4
GR - Grecia 4
HR - Croazia 4
IR - Iran 4
PS - Palestinian Territory 4
RS - Serbia 4
SC - Seychelles 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
BY - Bielorussia 3
DK - Danimarca 3
ET - Etiopia 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
UY - Uruguay 3
AU - Australia 2
CY - Cipro 2
GA - Gabon 2
LV - Lettonia 2
NG - Nigeria 2
QA - Qatar 2
SV - El Salvador 2
A1 - Anonimo 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
Totale 24.095
Salva come PNG Salva come JPEG
Città #
Dallas 2.975
Singapore 1.139
Ashburn 793
Dublin 745
Chandler 737
San Jose 643
Parma 537
Santa Clara 492
Ann Arbor 434
Beijing 432
Hong Kong 412
Jacksonville 360
Ho Chi Minh City 350
Dearborn 309
Boardman 267
Hanoi 250
Johannesburg 238
Munich 234
New York 180
Los Angeles 170
Nanjing 156
Shanghai 153
Izmir 151
Helsinki 137
Milan 133
Princeton 130
Hefei 128
Lauterbourg 124
Wilmington 110
Bremen 107
Bologna 102
San Mateo 79
São Paulo 71
Buffalo 68
Toronto 63
Council Bluffs 60
Shenyang 59
Brussels 58
Columbus 58
Kunming 57
Moscow 57
Abidjan 56
Vienna 52
Hebei 48
Jinan 48
Nanchang 47
Modena 46
Rome 46
Guangzhou 43
Turku 43
Frankfurt am Main 42
Haiphong 42
Seattle 41
Tokyo 41
Da Nang 40
Chicago 36
London 35
Woodbridge 35
Rio de Janeiro 33
Des Moines 32
Brescia 31
Bengaluru 30
Orem 30
Changsha 29
The Dalles 29
Tianjin 29
Jiaxing 28
Bangalore 27
Seoul 27
Brooklyn 25
Hangzhou 24
Jakarta 24
Montreal 24
Nuremberg 24
Fremont 23
Houston 23
Reggio Emilia 23
Lubbock 21
Belo Horizonte 20
Boston 20
Düsseldorf 20
Mexico City 20
Stockholm 20
Turin 20
Ottawa 19
Phoenix 19
Piacenza 19
Brno 18
Grafing 17
Amman 16
Amsterdam 16
Denver 16
Pune 16
Warsaw 16
Atlanta 15
Biên Hòa 15
Brasília 15
Chennai 15
Florence 15
Hillsboro 15
Totale 15.417
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.699
1,5-Benzodiazepines Part XIII. Substututed 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines and 4H-imidazo-[1,2-a][ 1,5]benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity 1.674
Principi di farmacognosia e fitoterapia. Seconda edizione 738
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 300
Principi di farmacognosia e fitoterapia 258
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 253
1,8-Naphthyridines V. Novel N-substituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity 252
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 251
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 251
Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats 247
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 243
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 223
Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador 219
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 219
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 219
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 218
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 217
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 210
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 202
Analgesic properties of benzisothiazole/ benzimidazole derivatives with acidic groups 200
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 198
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 197
1,8-Naphthyridines VII. New substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity. 193
1,8-Naphthyridines VIII. Novel 5-aminoimidazo[1,2-a] [1,8]naphthyridine-6-carboxamide and 5-amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. 192
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 190
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 190
2,4-Substituted benzopyrano[4,3-d]pyrimidines and benzopyrano[4,3-d]pyrimidin-5-ones: synthesis and antiplatelet activity 189
2-Amino-1,2-benzisothiazolin-3-one derivatives as powerful antiplatelet agents 185
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 185
A simple GC-MS method for the screening of betulinic, corosolic, maslinic, oleanolic and ursolic acid contents in commercial botanicals used as food supplement ingredients 183
Enhanced photosensitizing properties of protein bound curcumin 179
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 178
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 177
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 176
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 176
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 174
Hypericin - apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells 172
inibitori eph-ephrin biodisponibili oralmente 171
A photosensitizing fusion protein with targeting capabilities 170
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 168
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 165
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 165
2-Amino-1,2-benzisothiazolin-3-one Derivatives: Synthesis and Assessment of their Antiplatelet/Spasmolytic Effects 164
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 163
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 163
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 163
Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity 161
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 161
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 161
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 159
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 158
5-Alkoxy-2-hydrazino and 5-methoxy-2-amino-5H[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological activity 157
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 156
Intestinal Hypoxia and reperfusion: role for Eph-ephrin system 155
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 151
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 151
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 151
Structure activity relationship of new EphA2 ligands 150
Influence of adenosine in the systemic and local injury caused by mesenteric ischemia-reperfusion in mice 150
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 150
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "Grosso" 149
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 149
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 148
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 148
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 148
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 147
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 147
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 145
High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction 144
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) 143
Discovery of natural extracts interfering with EphA2-ephrinA1 system 143
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 141
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 140
Target-hopping: a useful approach to identify novel Eph receptor antagonists 139
2-Amino/azido/hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological evaluation 139
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 138
Computer-Aided Design of Novel Antagonists of the EphA2 Receptor 137
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 136
Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin 134
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 134
RESPONSIVENESS OF LONGITUDINAL AND CIRCULAR MUSCLE TO RELAXING MEDIATORS IS DIFFERENTIALLY AFFECTED IN RAT HYPERTROPHIED ILEUM 133
Disruption of Eph-ephrin B signaling pathways mitigates inflammation in a murine model of Crohn’s disease 133
Protection by the EPH-EPHRIN System Against Mesenteric Ischemia-Reperfusion Injury 132
Evidence for the involvement of 5-HT(2A) receptors in mild mesenteric ischemia/reperfusion dysfunctions in mice 131
Pharmacological screening of novel antiplatelet agents with analgesic activity 129
Mesenteric ischemia-reperfusion: an overview of preclinical drug strategies 128
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 127
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 127
Are we using the right pharmacological tools to target EphA4? 127
Synthesis and Biological Evaluation of N-Pyrazolyl-N'-alkyl/benzyl/phenylureas: a New Class of Potent Inhibitors of Interleukin 8-Induced Neutrophil Chemotaxis 126
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 126
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 125
Progress in 5H [1] benzopyrano[4,3-d]pyrimidin-5-amine series: “-methoxy derivatives effective as antiìplatelet agents with analgesic activity 124
New insights into the pharmacological properties of potent antiplatelet 2-amino-benzo|d|isothiazol-3-one derivatives 124
5-substituted derivatives of 6-amino-1,3-diphenyl-2-thioxo-2.3-dihydropyrimidin-4(1H9-one as a new class of potent inhibitors of interleukin 8-induced chemotaxis 124
PHENYLPROPANOID RICH ESSENTIAL OILS AS POTENTIAL ANTITHROMBOTICS ENDOWED WITH GASTROPROTECTIVE EFFECTS 123
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 123
6-amino-4-oxo-1,3-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl derivatives as a new class of potent inhibitors of Interleukin-8-induced neutrophil chemotaxis. 121
Beneficial effects of blocking EphBs-ephrinBs forward signalling in a murine Crohn’s sisease (CD) model 119
Effects of subacute treatment with benzopyranopyrimidines in hemostasis and experimental thrombosis in mice 119
Totale 20.260
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.319
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.319
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202144 0 0 0 0 0 0 0 0 0 0 0 44
2021/2022844 35 31 32 100 41 35 81 87 59 74 57 212
2022/20232.958 330 302 157 237 320 333 64 162 876 43 96 38
2023/20241.195 68 75 32 45 91 229 117 82 60 111 118 167
2024/20254.051 127 197 275 214 398 429 232 242 539 373 360 665
2025/202610.647 730 1.326 2.863 736 1.003 467 869 276 1.107 661 355 254
Totale 24.346